Cargando…

Psoriasis patients utilizing secukinumab, ixekizumab, or brodalumab – comparisons to prior biologic medication adherence levels, reasons for switching, and reported changes in disease symptoms

Background: Since the approval of interleukin-17 (IL-17) inhibitors to treat psoriasis progression, an increasing number of patients have switched to these third-generation biologics (i.e. secukinumab, ixekizumab, or brodalumab). Little is known about the impact of the new therapy choices upon patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Baiano, Renee, Staskon, Francis, Miller, Rick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764379/
http://dx.doi.org/10.1080/21556660.2019.1658298